AustralianSuper’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $140M | Buy |
4,980,592
+330,560
| +7% | +$8.8M | 0.73% | 28 |
|
|
2025
Q4 | $116M | Buy |
4,650,032
+671,258
| +17% | +$16.9M | 0.54% | 40 |
|
|
2025
Q3 | $101M | Buy |
3,978,774
+1,675,415
| +73% | +$41.4M | 0.48% | 46 |
|
|
2025
Q2 | $55.8M | Buy |
2,303,359
+1,987,425
| +629% | +$46.3M | 0.28% | 84 |
|
|
2025
Q1 | $8.01M | Hold |
315,934
| – | – | 0.05% | 153 |
|
|
2024
Q4 | $8.38M | Buy |
+315,934
| New | +$8.57M | 0.04% | 142 |
|
|
2024
Q2 | – | Sell |
-3,133,312
| Closed | -$86.9M | – | 261 |
|
|
2024
Q1 | $86.9M | Buy |
3,133,312
+2,198,342
| +235% | +$61M | 0.51% | 62 |
|
|
2023
Q4 | $26.9M | Sell |
934,970
-2,182,384
| -70% | -$66M | 0.16% | 97 |
|
|
2023
Q3 | $103M | Buy |
3,117,354
+418,332
| +15% | +$14.8M | 0.67% | 40 |
|
|
2023
Q2 | $99M | Buy |
+2,699,022
| New | +$105M | 0.63% | 42 |
|
|
2023
Q1 | – | Sell |
-2,477,896
| Closed | -$127M | – | 225 |
|
|
2022
Q4 | $127M | Buy |
2,477,896
+178,427
| +8% | +$8.55M | 0.84% | 33 |
|
|
2022
Q3 | $101K | Buy |
+2,299,469
| New | +$112M | 0.72% | 37 |
|
|
2022
Q2 | – | Sell |
-518,234
| Closed | -$26.8K | – | 192 |
|
|
2022
Q1 | $26.8K | Buy |
518,234
+286,459
| +124% | +$14.9M | 0.15% | 105 |
|
|
2021
Q4 | $12.6K | Sell |
231,775
-234,059
| -50% | -$11.6M | 0.07% | 155 |
|
|
2021
Q3 | $20M | Buy |
465,834
+150,005
| +47% | +$6.65M | 0.13% | 108 |
|
|
2021
Q2 | $12.4M | Buy |
315,829
+4,157
| +1% | +$162K | 0.09% | 126 |
|
|
2021
Q1 | $11.3M | Sell |
311,672
-1,573,987
| -83% | -$55.9M | 0.09% | 121 |
|
|
2020
Q4 | $69.4M | Buy |
1,885,659
+76,264
| +4% | +$2.8M | 0.52% | 51 |
|
|
2020
Q3 | $63M | Buy |
1,809,395
+34,120
| +2% | +$1.2M | 0.54% | 51 |
|
|
2020
Q2 | $55.1M | Sell |
1,775,275
-62,985
| -3% | -$2.14M | 0.53% | 51 |
|
|
2020
Q1 | $56.9M | Buy |
1,838,260
+743,257
| +68% | +$25.3M | 0.73% | 42 |
|
|
2019
Q4 | $40.7M | Buy |
1,095,003
+854,476
| +355% | +$30.4M | 0.34% | 56 |
|
|
2019
Q3 | $8.2M | Buy |
+240,527
| New | +$8.75M | 0.08% | 117 |
|
|
2019
Q2 | – | Sell |
-357,762
| Closed | -$14.4M | – | 159 |
|
|
2019
Q1 | $14.4M | Buy |
357,762
+219,111
| +158% | +$8.77M | 0.15% | 87 |
|
|
2018
Q4 | $5.74M | Buy |
138,651
+35,781
| +35% | +$1.49M | 0.09% | 63 |
|
|
2018
Q3 | $4.3M | Buy |
102,870
+15,388
| +18% | +$592K | 0.08% | 50 |
|
|
2018
Q2 | $3.01M | Buy |
+87,482
| New | +$2.99M | 0.07% | 53 |
|
|
2017
Q3 | – | Sell |
-761,304
| Closed | -$24.3M | – | 53 |
|
|
2017
Q2 | $24.3M | Buy |
761,304
+21,080
| +3% | +$665K | 1.87% | 23 |
|
|
2017
Q1 | $24M | Sell |
740,224
-62,713
| -8% | -$1.98M | 2.75% | 14 |
|
|
2016
Q4 | $24.7M | Buy |
+802,937
| New | +$24.5M | 3.94% | 12 |
|
Other funds holding PFE
VCM
VPM
AustralianSuper's PFE Position: Q1 2026 in Review
AustralianSuper increased its Pfizer (PFE) stake by 7.1% in Q1 2026, buying an estimated $8.8M and bringing the position to 4,980,592 shares worth $140M. The position accounts for 0.73% of the portfolio, ranked #28.
AustralianSuper first reported a position in PFE in Q4 2016 and has held it in 30 quarters since. 2,946 funds tracked by Wall St. Rank hold PFE as of Q1 2026.
- AustralianSuper held 4,980,592 shares of Pfizer worth $140M as of Q1 2026.
- AustralianSuper bought 330,560 Pfizer shares in Q1 2026, an estimated $8.8M.
- Pfizer made up 0.73% of AustralianSuper's portfolio in Q1 2026, its #28 holding.
- AustralianSuper first reported a position in Pfizer in Q4 2016 and has held it in 30 quarters since.
- 2,946 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.
Based on AustralianSuper's 13F filing for Q1 2026, filed 7 May 2026.